Jarden also has a commanding lead in the outdoor equipment market and is, in fact, the world's largest supplier of such equipment. Franklin said whether it's lanterns, snowboards, tents or sleeping bags, Jarden probably has a new, innovative product to show you.
Among Jarden's other accomplishments is its share price. The company recently performed a $500 million Dutch tender offer for its own shares. Franklin explained that during times when Jarden can't find a new brand to invest in, it is choosing to invest in itself by buying back shares to reward shareholders. Yet, despite the company's bold move, shares still trade at a paltry 11 times earnings.
Cramer continued his recommendation on Jarden.
Was the 20% jump higher in
(FB - Get Report)
justified? It was, according to Cramer, and the company may just be getting started after what remains the worst initial public offering in the history of the stock market.
Facebook not only had a terrific quarter but also a great conference call, one where it gave analysts and investors the answers they've been seeking for months. Facebook proved that its mobile strategy is in full swing now that its service is tightly integrated into the iPhone. A full 70% of users are now using Facebook on mobile devices and advertisers apparently love it. Facebook is now turning its attention to
Facebook also indicated that the problems with
did not spill over into the overall gaming sector, which was the fear of many investors. Zynga now represents just 7% of Facebook sales, down from 12%.
Cramer said the strength in Facebook's quarter may be strong enough to overpower the share lockup expirations coming due soon, and he would be a buyer on weakness.
In the Lightning Round, Cramer was bullish on
American Capital Agency
Cramer was bearish on
In the Pipeline
In his second "Executive Decision" segment, Cramer sat down with Dr. Francois Nader, president and CEO of
, an "orphan" drug maker that Cramer recommended on Sept 18. Shares of NPS spiked up 31% a month later on Oct. 12, at which time Cramer advised selling the stock. But he now says it may be worth investing in again as NPS has more than one new drug in its pipeline.